Dietary fiber‐based oral nanovaccine promotes gut‐to‐nose trafficking of regulatory cells and drives antigen‐specific tolerance to relieve airway allergy

Yuting Qin, Zeming Wang, Yuru Zong, Zefang Lu, Junxiu Liu, Ruifang Zhao, Guangjun Nie, Hanqing Chen · 2026

Read Dietary fiber‐based oral nanovaccine promotes gut‐to‐nose trafficking of regulatory cells and drives antigen‐specific tolerance to relieve airway allergy by Yuting Qin, Zeming Wang, Yuru Zong, Zefang Lu, Junxiu Liu, Ruifang Zhao, Guangjun Nie, Hanqing Chen (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13401610.txt.

Description

Yuting Qin and colleagues developed a 2026 oral nanovaccine made from dietary fibre that aims to teach lasting tolerance in allergic rhinitis rather than merely ease symptoms. Antihistamines and nasal steroids relieve the condition, which affects over 400 million people, but they do not cure it.

Their platform uses dextran fibre as both allergen carrier and food for gut bacteria. As intestinal microbes ferment it, short-chain fatty acids are released steadily alongside the allergen. Those acids, acting through the FFAR2 receptor, expand regulatory B and T cells, which then travel from gut to nasal lining. In mouse models the vaccine slowed disease progression, improved airway function, and cut allergen-specific IgE levels. The authors frame the gut-to-nose route as a path to durable protection against allergic airway disease.

Catalog record

CREATORYuting Qin, Zeming Wang, Yuru Zong, Zefang Lu, Junxiu Liu, Ruifang Zhao, Guangjun Nie, Hanqing Chen
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE28 KB
LICENSEhttps://creativecommons.org/licenses/by/4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/article/MED/PMC13401610

Browse the full library · About the Tower of Babel